With a strong financial position, we believe Neurocrine Biosciences (NBIX) is in an outstanding position to build shareholder value over the next several years.
The company exited the third quarter with $130 million in cash and receivables, with the potential to earn several hundred million more as clinical development progresses. The company’s dramatically improved financial position affords management the opportunity to push forward the development of internal pipeline candidates, including VMAT-2, as well as in-license new pre-phase II molecules within the company’s core CNS focus.
We recommend accumulating the stock at today’s price, up to our $12 target.
By Jason Napodano